The short version of GIP receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-05 and is reviewed periodically as new material appears.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Purity assay | 95 percent or greater by RP-HPLC | Typical research-grade specification |
| Storage temperature | 2 to 8 degrees Celsius | Formulated solution, do not freeze |
| Common analytical method | LC-MS with peptide mapping | Identity and impurity confirmation |
| Primary degradation routes | Deamidation, oxidation, aggregation | Tracked in stability programs |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
==== Australia ==== MMDA is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.
=== Electroplating === Cadmium electroplating, consuming 6% of the global production, is used in the aircraft industry to reduce corrosion of steel components. This coating is passivated by chromate salts. A limitation of cadmium plating is hydrogen embrittlement of high-strength steels from the electroplating process. Therefore, steel parts heat-treated to tensile strength above 1300 MPa (200 ksi) should be coated by an alternative method (such as special low-embrittlement cadmium electroplating processes or physical vapor deposition). Titanium embrittlement from cadmium-plated tool residues resulted in banishment of those tools (and the implementation of routine tool testing to detect cadmium contamination) in the A-12/SR-71, U-2, and subsequent aircraft programs that use titanium.
Commonly, a faggot consists of minced pork liver and heart, with onion and breadcrumbs. The mixture is shaped by hand into small balls, wrapped with caul fat (the omentum membrane from the pig's kidney) and baked. Faggots may also be made with beef. Another variation of the faggot is pig's fry (testicles) wrapped in pig's caul: the pig's fry and boiled onions are minced (ground) together, then mixed with breadcrumbs or cold boiled potatoes, seasoned with sage, mixed herbs and pepper, all beaten together and then wrapped in small pieces of caul to form a ball. They are baked in the oven, and usually served cold.
Sources: en.wikipedia.org
shall be loyal to the Union and its citizens; shall be a citizen of Myanmar who was born of both parents who were born in the territory under the jurisdiction of the Union and being Myanmar Nationals; shall be an elected person who has attained at least the age of 45; shall be well acquainted with the affairs of the Union such as political, administrative, economic and military; shall be a person who has resided continuously in the Union for at least 20 years up to the time of his election as President(Proviso: An official period of stay in a foreign country with the permission of the Union shall be counted as a residing period in the Union) shall he himself, one of the parents, the spouse, one of the legitimate children or their spouses not owe allegiance to a foreign power, not be subject of a foreign power or citizen of a foreign country. They shall not be persons entitled to enjoy the rights and privileges of a subject of a foreign government or citizen of a foreign country; shall possess prescribed qualifications of the President, in addition to qualifications prescribed to stand for election to the Hluttaw. Moreover, upon taking oath in office, the president is constitutionally forbidden from taking part in any political party activities (Chapter III, 64).
==== OXA-48-like carbapenemases ==== The spread of OXA-48 carbapenem resistance involves both the expansion of successful bacterial clones and the movement of blaOXA-48 between bacteria on mobile genetic elements. The gene is commonly associated with Tn1999-family transposons carried on highly conjugative IncL plasmids, although OXA-48-like genes also occur in other plasmid types and chromosomal contexts. A community outbreak in New Zealand during 2018–2022 involved 25 patients with OXA-48-producing Escherichia coli sequence type 131. Eighteen patients had visited the same community food premises, where four food handlers were also found to be colonized, and whole-genome sequencing demonstrated genomic links between patient and food-handler isolates. Subsequent long-read genomic analysis found that the outbreak lineage had acquired blaOXA-48 on a 7,872-base-pair Col156 plasmid and identified a single IS1-mediated transposition of the resistance gene into the Col156 plasmid backbone. Analysis of global genomic data showed that blaOXA-48 occurs in diverse plasmid and insertion-sequence contexts among Enterobacterales.
For example, γδ T cells express a T-cell receptor comprising γ and δ chains instead of the α and β chains that conventional T cell receptors use, and they are able to recognize antigen without the need for presenting it on MHC proteins (though some have shown the ability to recognize MHC-presented antigens), instead having a mode of recognition that resembles that of antibodies, or recognizing phosphoantigens (antigens that are phosphorylated) through butyrophilin. Mucosa-associated invariant T cells (MAIT) cells recognize ligands presented by the MHC-related protein MR1, which presents metabolites of riboflavin, pyridoxine, and folates. NKT cells recognize glycolipid antigens presented on CD1d, most prominently α-galactosylceramide. In contrast to T cell receptors, antibodies can recognize any type of molecule at virtually any size and can recognize either linear or conformational epitopes (the amino acids that comprise an epitope do not need to be next to each other in the primary structure but do need to be near one another when the protein is folded). At the molecular level, an antigen can be characterized by its ability to bind to an antibody's paratopes. Different antibodies have the potential to discriminate among specific epitopes present on the antigen surface.
Geographic data related to Portugal at OpenStreetMap National English language newspaper National Wine Website News about Portugal from the Portuguese American Journal Portugal at UCB Libraries GovPubs Portugal profile from the BBC News Prestage, Edgar; Jayne, Kingsley Garland (1911). "Portugal" . Encyclopædia Britannica. Vol. 22 (11th ed.). p. 134–163. Portuguese Pamphlets Collection from the Rare Book and Special Collections Division at the Library of Congress Wikimedia Atlas of Portugal Government Official Parliament website Official Portuguese Government website (in English and Portuguese) Trade World Bank Summary Trade Statistics Portugal Travel Official Portuguese Government Travel/media website Official Travel and Tourism office website
Sources: en.wikipedia.org
== History == Chloral hydrate was first synthesized by the chemist Justus von Liebig in 1832 at the University of Giessen. Liebig discovered the molecule when a chlorination (halogenation) reaction was performed on ethanol. Its sedative properties were observed by Rudolf Buchheim in 1861, but described in detail and published only in 1869 by Oscar Liebreich; subsequently, because of its easy synthesis, its use became widespread. Through experimentation, physiologist Claude Bernard clarified that the chloral hydrate was hypnotic as opposed to an analgesic. It was the first of a long line of sedatives, most notably the barbiturates, manufactured and marketed by the German pharmaceutical industry. Historically, chloral hydrate was utilized primarily as a psychiatric medication. In 1869, German physician and pharmacologist Oscar Liebreich began to promote its use to calm anxiety, especially when it caused insomnia. Chloral hydrate had certain advantages over morphine for this application, as it worked quickly without injection and had a consistent strength. The compound achieved wide use in both asylums and the homes of those socially refined enough to avoid asylums. Upper- and middle-class women, well-represented in the latter category, were particularly susceptible to chloral hydrate addiction. After the 1904 invention of barbital, the first of the barbiturate family, chloral hydrate began to disappear from use among those with means. It remained common in asylums and hospitals until the Second World War as it was quite cheap.
GLaDOS (Genetic Lifeform and Disk Operating System) is a rampant artificial intelligence computer system that controls Aperture Laboratories, and is the primary antagonist for the Portal series. She is voiced by Ellen McLain. She awakens the player-character Chell in the first game, tasking her through the dangerous testing course, but Chell manages to escape and appears to destroy her, though later revealed to have had her personality stored within a black box. Within the second game, Wheatley accidentally reawakens GLaDOS, and eventually convinces Chell to initiate a core transfer to replace her with himself. GLaDOS, placed into a module powered by a potato battery, is forced to work with Chell to depose Wheatley from power before the Aperture facility is destroyed. While exploring the older sections of the facility with GLaDOS's potato battery form (known informally as "PotatOS" by fans), it is revealed that her consciousness is based, at least in part, on an uploaded version of Cave Johnson's assistant, Caroline. Caroline was unwilling to be uploaded to a computer, but was forced to do so by Cave. This potentially contributed to GLaDOS's homicidal tendencies, alongside the mental adjustments and tweaking performed by the scientists working on her. In the tie-in comic Portal 2: Lab Rat, it is revealed that the personality cores, such as Wheatley, were attached to GLaDOS in an attempt to manage and control her by acting as an artificial "conscience." Discussing the morality core, scientist Doug Rattmann quips, "You can always ignore your conscience."
Urocortin III, a 38–41 amino acid peptide, is a member of the CRF (corticotropin-releasing factor), also known as CRH (corticotropin-releasing hormone) family of peptides, with a long evolutionary lineage. Separate chromosomes harbouring two exons each are home to the genes encoding UCN, UCN2, and UCN3. A gene on human chromosome 10p15 at location 5.40 Mb encodes the urocortin, UCN III, which has been discovered more recently. A 161 amino acid precursor is produced when the UCN III gene is translated. Mature UCN III with 38 or 41 amino acids would be produced by proteolytic cleavage between arginine- or threonine-lysine residues. Human plasma contains both the 38 and 41 amino acid forms of UCN III, although the 38 amino acid form is more prevalent, according to findings from high-performance liquid chromatography. Each urocortin peptide has a distinct expression location and function, yet they all share conserved structural similarity. Urocortins' structures, as determined by nuclear magnetic resonance, exhibit alpha-helical secondary structures, which support biological activity and binding selectivity.
The statue of Augustus of Prima Porta was discovered within the Villa of Livia in 1863. Little is known about the discovery itself and its immediate aftermath, as the incomplete archaeological journals leave ambiguous evidence for modern historians. The statue was first publicized by the German archaeologist Wilhelm Henzen in 1863 in the Bulletino dell'Instituto di Corrispondenza Archaeologica. The exact location of the statue within the villa is unknown. Suggested sites are the underground complex, a placement near a staircase, the villa's atrium, or in a laurel grove on the southeast corner of Prima Porta hill. Scholars have stated that the last one is relatively unconvincing compared with the first three. The theory that Augustus's statue was found in the underground complex of the villa is based on a hypothesis that Augustus holds a laurel branch instead of a spear in his left hand. Scholars have noted that if this hypothesis is correct, then Villa of Livia must have been decorated with laurel groves and that the reason of the decoration is the omen of the gallina alba (Latin: white hen). Recent excavations have discovered the remnants of pots used to plant laurel on the edge of the Prima Porta hill in front of the underground complex, which Reeder believes suggests the possibility of the existence of laurel groves in the villa and makes it likely that the statue was located in the underground complex.
=== Radio wave absorption === Stacked graphene layers on a quartz substrate increased the absorption of millimeter (radio) waves by 90 per cent over 125–165 GHz bandwidth, extensible to microwave and low-terahertz frequencies, while remaining transparent to visible light. For example, graphene could be used as a coating for buildings or windows to block radio waves. Absorption is a result of mutually coupled Fabry–Perot resonators represented by each graphene-quartz substrate. A repeated transfer-and-etch process was used to control surface resistivity.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.
Cycling between frozen and liquid states concentrates the peptide at ice interfaces, which favors non-covalent association. The resulting aggregates may be invisible to simple assays yet alter recovery and apparent potency. Limiting the number of cycles and aliquoting before storage are common mitigations.
Tryptophan and methionine side chains can undergo photo-induced oxidation, so amber glass or opaque packaging is typical. The effect is gradual and depends on wavelength and exposure time. Light protection is usually specified for both solid and solution forms.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.